Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Deferred Revenue (2022 - 2025)

NewAmsterdam Pharma's Current Deferred Revenue history spans 4 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 33.64% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, down 33.64%, while the annual FY2025 figure was $4.0 million, 33.64% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $4.0 million at NewAmsterdam Pharma, up from $3.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $18.7 million in Q4 2022 and bottomed at $3.0 million in Q1 2025.
  • The 4-year median for Current Deferred Revenue is $6.0 million (2024), against an average of $7.5 million.
  • The largest YoY upside for Current Deferred Revenue was 33.64% in 2025 against a maximum downside of 62.67% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $18.7 million in 2022, then crashed by 46.64% to $10.0 million in 2023, then tumbled by 39.68% to $6.0 million in 2024, then plummeted by 33.64% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Current Deferred Revenue are $4.0 million (Q4 2025), $3.0 million (Q1 2025), and $6.0 million (Q4 2024).